Otoharmonics Corporation has announced the US patent approval for certain elements of the company’s Levo tinnitus system. Otoharmonics reports that, utilizing an FDA-cleared neuroscience-based approach, the Levo System offers a patented method to provide personalized sound therapy while sleeping.

“This is a significant advancement in tinnitus care,” said Michael Baker, CEO and President of Otoharmonics. “Patent approval reinforces what we already know: The Levo System stands apart from every other tinnitus therapy on the market.”

According to Otoharmonics, the Levo System was specifically designed for use during sleep and has a patented sound matching method to identify a patient’s unique tinnitus sound. The system offers the ability to hear what patients hear and develop personalized therapy. It can track patient use and response to therapy using a method that leverages smart technology, and integrates the Tinnitus Functional Index (TFI) to measure and monitor tinnitus impact on quality of life. The Levo tinnitus system is FDA-cleared as a medical device using Apple hardware and proprietary software, and has high-fidelity custom-fit ear buds.

To learn more about the Levo System visit the Otoharmonics website.

Source: Otoharmonics Corporation